A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.

@article{Liang2017ANV,
  title={A New Viscous Cysteamine Eye Drops Treatment for Ophthalmic Cystinosis: An Open-Label Randomized Comparative Phase III Pivotal Study.},
  author={Hong Liang and Antoine Labb{\'e} and Jeannie Le Mouha{\"e}r and C{\'e}line Plisson and Christophe Baudouin},
  journal={Investigative ophthalmology & visual science},
  year={2017},
  volume={58 4},
  pages={2275-2283}
}
Purpose The purpose of this study was to evaluate the efficacy of new viscous cysteamine hydrochloride (CH) eye drops (vCH 0.55%) compared with standard CH 0.10% drops treatment. Methods This was an open-label, phase III, randomized, two-arm multicenter trial conducted at two centers in France. Cystinosis patients ≥2 years old were randomized 1:1 to receive eye drops, four times per day for 90 days in both eyes. We compared the superiority in reducing corneal cystine crystal density as… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells

  • C Debbasch, SB De La Salle, F Brignole, P Rat, JM Warnet, C. Baudouin
  • 2002

Similar Papers

Loading similar papers…